Lumosa is proud to announce the approval of Phase 2, multi-dose trial of LT3001 in patients with acute ischemic stroke by Taiwan FDA. The company will soon initiate the multi-national, multi-site study, in the US and Taiwan. The trial will enroll 200 patients with disabling acute ischemic stroke within 24 hours of stroke symptom onset or last known well.